A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

PHASE3UnknownINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions
DementiaAlzheimer's Disease
Interventions
DRUG

[18F]NAV4694

Trial Locations (15)

10461

Albert Einstein College of Medicine, The Bronx

27157

Wake Forest Baptist Health-Gerontology, Winston-Salem

27559

The University of North Carolina at Chapel Hill, Chapel Hill

32806

Compass Research, Orlando

33140

Mount Sinai Medical Center of Florida, Miami Beach

33166

Galiz Research, Miami Springs

33912

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

34239

Physicians Care Clinical Research, Sarasota

45459

Valley Medical Center, Centerville

60612

Rush University Medical Center, Chicago

62702

Southern Illinois University School of Medicine, Springfield

71103

Biomedical Research Foundation, Shreveport

85351

Banner Sun Health Research Institute, Sun City

89113

Las Vegas Radiology, Las Vegas

92093

University of California San Diego, La Jolla

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY